866-997-4948(US-Canada Toll Free)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 486 Pages

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 7
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Development 8
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Assessment 25
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Companies Involved in Therapeutics Development 39
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drug Profiles 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Dormant Projects 452
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Discontinued Products 456
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Product Development Milestones 458
Appendix 474

List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 19
Number of Products under Development by Companies, H1 2017 21
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 22
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 23
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 24
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 25
Number of Products under Development by Universities/Institutes, H1 2017 26
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 28
Products under Development by Companies, H1 2017 29
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 30
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 31
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 32
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 33
Products under Development by Universities/Institutes, H1 2017 34
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 35
Number of Products by Stage and Target, H1 2017 37
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 38
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 39
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 40
Number of Products by Stage and Mechanism of Action, H1 2017 42
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 43
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 44
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 45
Number of Products by Stage and Route of Administration, H1 2017 47
Number of Products by Stage and Molecule Type, H1 2017 49
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by AbbVie Inc, H1 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Altor BioScience Corp, H1 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by arGEN-X BV, H1 2017 51
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Ariad Pharmaceuticals Inc, H1 2017 52
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Array BioPharma Inc, H1 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Astex Pharmaceuticals Inc, H1 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Atara Biotherapeutics Inc, H1 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Bio-Path Holdings Inc, H1 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by BioLineRx Ltd, H1 2017 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by BioSight Ltd, H1 2017 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by BLR Bio LLC, H1 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Boston Biomedical Inc, H1 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Bristol-Myers Squibb Company, H1 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Cantargia AB, H1 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Celgene Corp, H1 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Cellectar Biosciences Inc, H1 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Cellectis SA, H1 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Cielo Therapeutics Inc, H1 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Constellation Pharmaceuticals Inc, H1 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Daiichi Sankyo Company Ltd, H1 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Eisai Co Ltd, H1 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by EpiZyme Inc, H1 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Galena Biopharma Inc, H1 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Gamida Cell Ltd, H1 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by GlaxoSmithKline Plc, H1 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by GlycoMimetics Inc, H1 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Hovione FarmaCiencia SA, H1 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Hybrigenics SA, H1 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Immune Pharmaceuticals Inc, H1 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Incyte Corp, H1 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Johnson & Johnson, H1 2017 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Juno Therapeutics Inc, H1 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by JW Pharmaceutical Corp, H1 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Karyopharm Therapeutics Inc, H1 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Mesoblast Ltd, H1 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Millennium Pharmaceuticals Inc, H1 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Natco Pharma Ltd, H1 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Novartis AG, H1 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by OncoImmune Inc, H1 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by OncoTherapy Science Inc, H1 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 73
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Oribase Pharma, H1 2017 73
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Pfizer Inc, H1 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Pharma Mar SA, H1 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by PharmaEssentia Corp, H1 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Phylogica Ltd, H1 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Selvita SA, H1 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Shenogen Pharma Group Ltd, H1 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by SignalChem Lifesciences Corp, H1 2017 77
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Stemline Therapeutics Inc, H1 2017 77
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 78
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Synactix Pharmaceuticals Inc, H1 2017 78
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Syndax Pharmaceuticals Inc, H1 2017 79
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 79
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by TRACON Pharmaceuticals Inc, H1 2017 80
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Tragara Pharmaceuticals Inc, H1 2017 80
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by VioQuest Pharmaceuticals Inc, H1 2017 81
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline by Xencor Inc, H1 2017 81
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Dormant Projects, H1 2017 463
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Dormant Projects, H1 2017 (Contd..1), H1 2017 464
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Dormant Projects, H1 2017 (Contd..2), H1 2017 465
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Dormant Projects, H1 2017 (Contd..3), H1 2017 466
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Discontinued Products, H1 2017 467
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Discontinued Products, H1 2017 (Contd..1), H1 2017 468

List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 19
Number of Products under Development by Companies, H1 2017 20
Number of Products under Development by Universities/Institutes, H1 2017 26
Number of Products by Top 10 Targets, H1 2017 36
Number of Products by Stage and Top 10 Targets, H1 2017 36
Number of Products by Top 10 Mechanism of Actions, H1 2017 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 41
Number of Products by Top 10 Routes of Administration, H1 2017 46
Number of Products by Stage and Top 10 Routes of Administration, H1 2017 46
Number of Products by Top 10 Molecule Types, H1 2017 48
Number of Products by Stage and Top 10 Molecule Types, H1 2017 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *